atezolizumab
roche
['sclc', 'atezo', 'nsclc', 'atezo-brain']
 #asco22 presented the atezo-brain trial with atezo + chemo in #nsclc pts with active brain mets. intracranial orr = 42.5%, systemic orr = 45%, intracranial pfs = 6.9 mos, systemic pfs = 8.9 mos, and 27.5% alive 2 yrs out. small population as well.
Dir. STEM Workforce Initiatives @LUNGevity. #BME, #Cancer, #Genomics, Dig. #Pathology, jujitsu, and outreach. Thoughts are my own. RT or follow != endorsement.